Trial Profile
Phase II Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Carboplatin; Paclitaxel
- Indications Cervical cancer
- Focus Therapeutic Use
- Sponsors Biotech Pharmaceutical
- 18 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Jan 2014 New trial record